Ana C Anderson

List of Publications by Year
in descending order

71 papers	16,063 citations	50276 46 h-index	95266 68 g-index
73 all docs	73 docs citations	73 times ranked	18705 citing authors

#	Article	IF	Citations
1	Presence of <scp>Tim</scp>3⁺ and <scp>PD</scp>â€1⁺<scp>CD8</scp>⁺<scp>T</scp> cells identifies microsatellite stable colorectal carcinomas with immune exhaustion and distinct clinicopathological features. Journal of Pathology, 2022, 257, 186-197.	4.5	13
2	Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function. Science Immunology, 2022, 7, eabm0631.	11.9	22
3	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. Journal of Clinical Investigation, 2022, 132, .	8.2	25
4	Male sex chromosomal complement exacerbates the pathogenicity of Th17 cells in a chronic model of central nervous system autoimmunity. Cell Reports, 2021, 34, 108833.	6.4	29
5	TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature, 2021, 595, 101-106.	27.8	169
6	PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nature Communications, 2021, 12, 4907.	12.8	18
7	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell, 2021, 184, 6262-6280.e26.	28.9	125
8	TIM3 comes of age as an inhibitory receptor. Nature Reviews Immunology, 2020, 20, 173-185.	22.7	535
9	An IL-27-Driven Transcriptional Network Identifies Regulators of IL-10 Expression across T Helper Cell Subsets. Cell Reports, 2020, 33, 108433.	6.4	54
10	Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. Immunity, 2020, 53, 658-671.e6.	14.3	98
11	Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight, 2020, 5, .	5.0	30
12	Going beyond a whackâ€aâ€mole game: A systems biology approach to immune tolerance. Clinical and Experimental Neuroimmunology, 2019, 10, 5-6.	1.0	0
13	Revolutionizing Cancer Immunology: The Power of Next-Generation Sequencing Technologies. Cancer Immunology Research, 2019, 7, 168-173.	3.4	10
14	Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1â^'CD8+ Tumor-Infiltrating T Cells. Immunity, 2019, 50, 181-194.e6.	14.3	424
15	Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. Journal of Immunology, 2018, 200, 3000-3007.	0.8	118
16	Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. OncoImmunology, 2018, 7, e1385690.	4.6	80
17	Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature, 2018, 558, 454-459.	27.8	336
18	<scp>TIGIT</scp> and <scp>CD</scp>96: new checkpoint receptor targets for cancer immunotherapy. Immunological Reviews, 2017, 276, 112-120.	6.0	351

#	Article	IF	Citations
19	Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 2016, 44, 989-1004.	14.3	1,538
20	A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell, 2016, 166, 1500-1511.e9.	28.9	315
21	TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection. PLoS Pathogens, 2016, 12, e1005490.	4.7	147
22	TIGIT predominantly regulates the immune response via regulatory T cells. Journal of Clinical Investigation, 2015, 125, 4053-4062.	8.2	470
23	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	4.6	119
24	A T cell extrinsic mechanism by which IL-2 dampens Th17 differentiation. Journal of Autoimmunity, 2015, 59, 38-42.	6.5	7
25	An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nature Communications, 2015, 6, 6072.	12.8	169
26	CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature, 2015, 517, 386-390.	27.8	525
27	Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. Current Opinion in HIV and AIDS, 2014, 9, 439-445.	3.8	64
28	Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape. Cancer Immunology Research, 2014, 2, 393-398.	3.4	278
29	Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T Cells. Immunity, 2014, 41, 270-282.	14.3	249
30	PD-1 and Tim-3 Regulate the Expansion of Tumor Antigenâ€“Specific CD8+ T Cells Induced by Melanoma Vaccines. Cancer Research, 2014, 74, 1045-1055.	0.9	179
31	Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. Cancer Immunology Research, 2014, 2, 410-422.	3.4	322
32	Tim-3 Regulation of Cancer Immunity. , 2014, , 239-261.		0
33	IL-1Î² Promotes Antimicrobial Immunity in Macrophages by Regulating TNFR Signaling and Caspase-3 Activation. Journal of Immunology, 2013, 190, 4196-4204.	0.8	180
34	TIM3⁺FOXP3⁺regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. OncoImmunology, 2013, 2, e23849.	4.6	251
35	A Transgenic Model of Central Nervous System Autoimmunity Mediated by CD4+ and CD8+ T and B Cells. Journal of Immunology, 2012, 188, 2084-2092.	0.8	59
36	Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood, 2012, 120, 682-690.	1.4	47

#	Article	IF	Citations
37	Bat3 promotes T cell responses and autoimmunity by repressing Tim-3â€“mediated cell death and exhaustion. Nature Medicine, 2012, 18, 1394-1400.	30.7	303
38	Immune checkpoints in central nervous system autoimmunity. Immunological Reviews, 2012, 248, 122-139.	6.0	90
39	Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends in Immunology, 2011, 32, 345-349.	6.8	215
40	Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 2011, 117, 4501-4510.	1.4	554
41	Differential IL-21 signaling in APCs leads to disparate Th17 differentiation in diabetes-susceptible NOD and diabetes-resistant NOD.Idd3 mice. Journal of Clinical Investigation, 2011, 121, 4303-4310.	8.2	46
42	Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine, 2010, 207, 2187-2194.	8.5	1,652
43	Tâ€bet, a Th1 transcription factor regulates the expression of Timâ€3. European Journal of Immunology, 2010, 40, 859-866.	2.9	98
44	Tim3 binding to galectin-9 stimulates antimicrobial immunity. Journal of Experimental Medicine, 2010, 207, 2343-2354.	8.5	165
45	Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14733-14738.	7.1	697
46	TIM-3 and Its Regulatory Role in Immune Responses. Current Topics in Microbiology and Immunology, 2010, 350, 1-15.	1.1	114
47	T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8706-8711.	7.1	163
48	Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells. Journal of Immunology, 2010, 185, 1383-1392.	0.8	243
49	New roles for TIM family members in immune regulation. Nature Reviews Immunology, 2008, 8, 577-580.	22.7	121
50	Role of Th1 and Th17 cells in organ-specific autoimmunity. Journal of Autoimmunity, 2008, 31, 252-256.	6.5	371
51	Cutting Edge: TheIdd3Genetic Interval Determines Regulatory T Cell Function through CD11b+CD11câ^' APC. Journal of Immunology, 2008, 181, 7449-7452.	0.8	18
52	TIM-4 Expressed on APCs Induces T Cell Expansion and Survival. Journal of Immunology, 2008, 180, 4706-4713.	0.8	96
53	Up-Regulation of Gene Related to Anergy in Lymphocytes Is Associated with Notch-Mediated Human T Cell Suppression. Journal of Immunology, 2007, 178, 6158-6163.	0.8	44
54	Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. Journal of Experimental Medicine, 2007, 204, 1691-1702.	8.5	117

#	Article	IF	Citations
55	Modulation of CD4 co-receptor limits spontaneous autoimmunity when high-affinity transgenic TCR specific for self-antigen is expressed on a genetically resistant background. International Immunology, 2007, 19, 1235-1248.	4.0	10
56	Tim Protein Structures Reveal a Unique Face for Ligand Binding. Immunity, 2007, 26, 273-275.	14.3	10
57	Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells. Science, 2007, 318, 1141-1143.	12.6	623
58	CD11b+Ly-6Chi Suppressive Monocytes in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2007, 179, 5228-5237.	0.8	313
59	Autoimmune Response and Immune Tolerance. , 2007, , 3-19.		0
60	TIM-3 in autoimmunity. Current Opinion in Immunology, 2006, 18, 665-669.	5.5	92
61	The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature Immunology, 2005, 6, 1245-1252.	14.5	1,697
62	Impairment of Thymocyte Development by Dominant-Negative Kuzbanian (ADAM-10) Is Rescued by the Notch Ligand, Delta-1. Journal of Immunology, 2005, 174, 6732-6741.	0.8	26
63	The Notch Regulator Numb Links the Notch and TCR Signaling Pathways. Journal of Immunology, 2005, 174, 890-897.	0.8	53
64	IL-10 Plays an Important Role in the Homeostatic Regulation of the Autoreactive Repertoire in Naive Mice. Journal of Immunology, 2004, 173, 828-834.	0.8	47
65	Expression of Self-antigen in the Thymus. Journal of Experimental Medicine, 2003, 198, 1627-1629.	8.5	29
66	T CELL RESPONSE IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE): Role of Self and Cross-Reactive Antigens in Shaping, Tuning, and Regulating the Autopathogenic T Cell Repertoire. Annual Review of Immunology, 2002, 20, 101-123.	21.8	336
67	Notch signaling in lymphocyte development. Current Opinion in Genetics and Development, 2001, 11, 554-560.	3.3	45
68	The origin and regulation of autopathogenic T cells. Journal of Clinical Immunology, 2001, 21, 74-80.	3.8	4
69	Autoantigen-Responsive T Cell Clones Demonstrate Unfocused TCR Cross-Reactivity toward Multiple Related Ligands: Implications for Autoimmunity. Cellular Immunology, 2000, 202, 88-96.	3.0	19
70	Tuning T cell activation threshold and effector function with cross-reactive peptide ligands. International Immunology, 2000, 12, 205-213.	4.0	40
71	High Frequency of Autoreactive Myelin Proteolipid Proteinâ€“Specific T Cells in the Periphery of Naive Mice. Journal of Experimental Medicine, 2000, 191, 761-770.	8.5	254